MA53835A - Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoires - Google Patents
Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoiresInfo
- Publication number
- MA53835A MA53835A MA053835A MA53835A MA53835A MA 53835 A MA53835 A MA 53835A MA 053835 A MA053835 A MA 053835A MA 53835 A MA53835 A MA 53835A MA 53835 A MA53835 A MA 53835A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- receptor
- treatment
- protein kinase
- inflammatory diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562188153P | 2015-07-02 | 2015-07-02 | |
US201562387295P | 2015-12-23 | 2015-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53835A true MA53835A (fr) | 2021-08-11 |
Family
ID=56411952
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA042302A MA42302A (fr) | 2015-07-02 | 2016-07-01 | Lactames bicycliques et leurs méthodes d'utilisation |
MA053835A MA53835A (fr) | 2015-07-02 | 2016-07-01 | Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoires |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA042302A MA42302A (fr) | 2015-07-02 | 2016-07-01 | Lactames bicycliques et leurs méthodes d'utilisation |
Country Status (25)
Country | Link |
---|---|
US (2) | US10988459B2 (fr) |
EP (2) | EP3317269B1 (fr) |
JP (2) | JP6785252B2 (fr) |
KR (2) | KR102603915B1 (fr) |
CN (3) | CN111269221B (fr) |
AU (4) | AU2016287581B2 (fr) |
CA (2) | CA2988601C (fr) |
CL (2) | CL2017003486A1 (fr) |
CO (1) | CO2017013709A2 (fr) |
CR (1) | CR20170573A (fr) |
ES (1) | ES2930749T3 (fr) |
HK (1) | HK1251899A1 (fr) |
IL (2) | IL255830B (fr) |
MA (2) | MA42302A (fr) |
MX (2) | MX2017016482A (fr) |
MY (1) | MY192762A (fr) |
PE (2) | PE20221048A1 (fr) |
PH (1) | PH12018500034A1 (fr) |
PL (1) | PL3317269T3 (fr) |
RU (1) | RU2716136C2 (fr) |
SG (1) | SG10201913880XA (fr) |
TW (2) | TWI788830B (fr) |
UA (1) | UA122150C2 (fr) |
WO (1) | WO2017004500A1 (fr) |
ZA (1) | ZA201707812B (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016287581B2 (en) | 2015-07-02 | 2019-06-06 | F. Hoffmann-La Roche Ag | Bicyclic lactams and methods of use thereof |
CA3002542C (fr) * | 2015-10-23 | 2023-11-28 | Takeda Pharmaceutical Company Limited | Derives heterocycliques d'azepine substitues et compositions utiles comme inhibiteur de rip1 kinase |
US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
SG10201913587WA (en) * | 2016-02-05 | 2020-02-27 | Denali Therapeutics Inc | Inhibitors of receptor-interacting protein kinase 1 |
JP7349359B2 (ja) * | 2016-10-17 | 2023-09-22 | エフ. ホフマン-ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
JP6890179B2 (ja) | 2016-12-02 | 2021-06-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 二環式アミド化合物及びその使用方法 |
ES2912295T3 (es) | 2016-12-09 | 2022-05-25 | Denali Therapeutics Inc | Compuestos útiles como inhibidores de RIPK1 |
US11072607B2 (en) * | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
BR112019017738A2 (pt) | 2017-02-27 | 2020-04-07 | Glaxosmithkline Ip Dev Ltd | combinação, composição farmacêutica, uso de uma combinação ou composição farmacêutica, método para tratar câncer em um humano, e, composto |
GB201706102D0 (en) * | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
CN107200737B (zh) * | 2017-06-29 | 2019-03-26 | 武汉药明康德新药开发有限公司 | 叔丁氧羰基-3-(羟甲基)-[1,2,3]三氮唑[1,5-a]哌啶-6-酰胺制法 |
SG11202000333UA (en) * | 2017-07-14 | 2020-02-27 | Hoffmann La Roche | Bicyclic ketone compounds and methods of use thereof |
SG11202003283TA (en) | 2017-10-11 | 2020-05-28 | Hoffmann La Roche | Bicyclic compounds for use as rip1 kinase inhibitors |
MX2020003451A (es) | 2017-10-31 | 2020-08-03 | Hoffmann La Roche | Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos. |
WO2019204537A1 (fr) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | Dérivés de n-[4-oxo-2,3-dihydro-1,5-benzoxazépin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide et composés apparentés en tant qu'inhibiteurs de la kinase rip1 pour le traitement, par exemple, du syndrome du côlon irritable (ibs) |
MD3788044T2 (ro) | 2018-05-03 | 2023-12-31 | Rigel Pharmaceuticals Inc | Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora |
PL3788045T3 (pl) | 2018-05-03 | 2023-10-09 | Rigel Pharmaceuticals, Inc. | Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania |
WO2020001420A1 (fr) * | 2018-06-26 | 2020-01-02 | 中国科学院上海有机化学研究所 | Inhibiteur de nécrose cellulaire, son procédé de préparation et son utilisation |
CN110642874B (zh) * | 2018-06-26 | 2023-03-28 | 中国科学院上海有机化学研究所 | 一类细胞坏死抑制剂及其制备方法和用途 |
WO2020044206A1 (fr) | 2018-08-29 | 2020-03-05 | Glaxosmithkline Intellectual Property Development Limited | Amides hétérocycliques utiles en tant qu'inhibiteurs de kinases destinés à être utilisés dans le traitement du cancer |
JP7467349B2 (ja) * | 2018-09-10 | 2024-04-15 | 科研製薬株式会社 | 新規ヘテロ芳香族アミド誘導体及びそれを含有する医薬 |
CN109134448B (zh) * | 2018-10-16 | 2020-11-27 | 中南大学湘雅医院 | 杂环化合物及其盐、制备方法、用途和药物 |
TW202043229A (zh) | 2019-01-11 | 2020-12-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環酮化合物及其使用方法 |
AU2020210455B2 (en) * | 2019-01-25 | 2023-02-02 | Beijing Scitech-Mq Pharmaceuticals Limited | Acylamino bridged heterocyclic compound, and composition and application thereof |
AR118243A1 (es) | 2019-03-07 | 2021-09-22 | Pi Industries Ltd | Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas |
EP3978492A4 (fr) * | 2019-05-31 | 2023-06-28 | Medshine Discovery Inc. | Composé bicyclique en tant qu'inhibiteur de la kinase rip-1 et son application |
CN110183442A (zh) * | 2019-06-06 | 2019-08-30 | 无锡合全药业有限公司 | 一种1 -(乙氧羰基)咪唑并[1, 5]吡啶-6-羧酸的合成方法 |
US11564930B2 (en) | 2019-09-06 | 2023-01-31 | Rigel Pharmaceuticals, Inc. | RIP1 inhibitory compounds and methods for making and using the same |
US11718612B2 (en) | 2019-09-06 | 2023-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase I for the treatment of disease |
EP4025568A1 (fr) | 2019-09-06 | 2022-07-13 | Rigel Pharmaceuticals, Inc. | Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation |
US11753381B2 (en) | 2019-09-27 | 2023-09-12 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase I for the treatment of disease |
CA3156594A1 (fr) | 2019-11-07 | 2021-05-14 | Yan Chen | Composes heterocycliques inhibiteurs de rip1 |
BR112022010082A2 (pt) * | 2019-11-26 | 2022-08-30 | Univ Texas | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica |
WO2021124155A1 (fr) | 2019-12-20 | 2021-06-24 | Pfizer Inc. | Dérivés de benzimidazole |
CA3169099A1 (fr) * | 2020-02-28 | 2021-09-02 | Board Of Regents, The University Of Texas System | Inhibiteurs de la proteine kinase i interagissant avec le recepteur pour le traitement d'une maladie |
AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
JP7477642B2 (ja) | 2020-04-09 | 2024-05-01 | ディスアーム セラピューティクス, インコーポレイテッド | Sarm1の阻害剤 |
BR112022023550A2 (pt) | 2020-05-19 | 2023-01-03 | Bayer Cropscience Ag | (tio)amidas azabicíclicas como compostos fungicidas |
US20230234945A1 (en) | 2020-06-10 | 2023-07-27 | Bayer Aktiengesellschaft | Azabicyclyl-substituted heterocycles as fungicides |
AR122703A1 (es) | 2020-07-01 | 2022-09-28 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
EP3974414A1 (fr) | 2020-09-25 | 2022-03-30 | Bayer AG | Pyrazoles et triazoles substitués par un 5-amino en tant que pesticides |
WO2022171111A1 (fr) * | 2021-02-10 | 2022-08-18 | Zai Lab (Us) Llc | Composé bicyclique fusionné hétéroaryle utile en tant qu'inhibiteur de la rip1-kinase et ses utilisations |
WO2022171110A1 (fr) * | 2021-02-10 | 2022-08-18 | Zai Lab (Us) Llc | Composés tricycliques fusionnés en tant qu'inhibiteurs de rip1-kinase et leurs utilisations |
TW202300490A (zh) * | 2021-03-11 | 2023-01-01 | 美商雷傑製藥公司 | 雜環rip1激酶抑制劑 |
BR112023020229A2 (pt) | 2021-04-02 | 2023-11-14 | Hoffmann La Roche | Processos para a preparação de um composto bicíclico de cetona quiral, composto de n-amino lactama quiral, composto de sal imidato e composto hidroxicetoéster, composto, ou um sal farmaceuticamente aceitável do mesmo e invenção |
CN113651810B (zh) * | 2021-07-16 | 2023-10-13 | 上海毕得医药科技股份有限公司 | 一种3-甲酰基-1H-吡唑并[3,4-b]吡啶-5-羧酸甲酯的合成方法 |
TW202321211A (zh) | 2021-08-10 | 2023-06-01 | 美商艾伯維有限公司 | 菸鹼醯胺ripk1抑制劑 |
WO2023020486A1 (fr) * | 2021-08-17 | 2023-02-23 | 广州市恒诺康医药科技有限公司 | Composé inhibiteur de la kinase rip1 et composition et utilisation associées |
US20230060797A1 (en) * | 2021-09-02 | 2023-03-02 | Jcr Pharmaceuticals Co., Ltd. | Therapeutic compound for neuronal ceroid lipofuscinosis |
WO2023119210A1 (fr) | 2021-12-24 | 2023-06-29 | 제일약품주식회사 | Nouveau composé utilisé en tant qu'inhibiteur de ripk1 et composition pharmaceutique le comprenant |
US11999750B2 (en) | 2022-01-12 | 2024-06-04 | Denali Therapeutics Inc. | Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide |
WO2023240379A1 (fr) * | 2022-06-13 | 2023-12-21 | 南京医工医药技术有限公司 | Dérivé d'imidazolinone et son utilisation |
WO2024013736A1 (fr) * | 2022-07-12 | 2024-01-18 | Adama Makhteshim Ltd. | Procédé de préparation de benzamides substitués |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206234A (en) | 1990-10-22 | 1993-04-27 | Merck & Co., Inc. | Benzolactam analogs as antagonists of cck |
JP4094066B2 (ja) | 1996-12-06 | 2008-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | インターロイキン−1β変換酵素のインヒビター |
GB0021831D0 (en) * | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
US20030113782A1 (en) | 2001-11-26 | 2003-06-19 | Karim Felix D. | MAP4Ks as modifiers of branching morphogenesis and methods of use |
US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
CA2502685A1 (fr) | 2002-10-23 | 2004-05-06 | Exelixis, Inc. | Cdkl1 utilise en tant que modificateur de la morphogenese de branchement, et procedes d'utilisation du cdkl1 |
US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
WO2007076927A1 (fr) | 2005-12-30 | 2007-07-12 | Merck Patent Gmbh | Antagonistes de l'interleukine 6 |
ATE469895T1 (de) | 2006-07-21 | 2010-06-15 | Vertex Pharma | Cgrp-rezeptorantagonisten |
WO2009140128A2 (fr) * | 2008-05-13 | 2009-11-19 | Irm Llc | Composés et compositions servant d'inhibiteurs de kinases |
US20130018039A1 (en) * | 2010-03-31 | 2013-01-17 | Bodmer Vera Q | Imidazolyl-imidazoles as kinase inhibitors |
GB201106817D0 (en) * | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
EP2773341A2 (fr) | 2011-10-21 | 2014-09-10 | Massachusetts Eye & Ear Infirmary | Compositions comprenant des inhibiteurs de la necrose, tels que des necrostatines, seuls ou en combinaison, pour la promotion de la régénération axonale et de la fonction nerveuse, ainsi pour traiter les maladies du snc |
US9611224B2 (en) | 2012-07-13 | 2017-04-04 | Hoffmann-La Roche Inc. | Antiproliferative benzo [B] azepin-2-ones |
CA2877048A1 (fr) | 2012-08-09 | 2014-02-13 | F. Hoffmann-La Roche Ag | Hetero-azepinones substituees |
TWI648274B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 (二) |
US9725452B2 (en) | 2013-03-15 | 2017-08-08 | Presidents And Fellows Of Harvard College | Substituted indoles and pyrroles as RIP kinase inhibitors |
WO2014170892A1 (fr) | 2013-04-15 | 2014-10-23 | Yeda Research And Development Co. Ltd. | Inhibition de rip kinases pour triater des maladies lysosomales |
BR112017003546A2 (pt) | 2014-08-21 | 2017-12-05 | Glaxosmithkline Ip Dev Ltd | amidas heterocíclicas como inibidores de rip1 quinase como medicamentos |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
KR20170004814A (ko) | 2015-07-02 | 2017-01-11 | 주식회사 녹십자 | 헌터증후군 치료제 |
SG10201913980SA (en) | 2015-07-02 | 2020-03-30 | Hoffmann La Roche | Benzoxazepin oxazolidinone compounds and methods of use |
CN108235704B (zh) | 2015-07-02 | 2021-10-26 | 爱尔兰詹森科学公司 | 抗细菌化合物 |
AU2016287581B2 (en) | 2015-07-02 | 2019-06-06 | F. Hoffmann-La Roche Ag | Bicyclic lactams and methods of use thereof |
US10709692B2 (en) | 2015-12-04 | 2020-07-14 | Denali Therapeutics Inc. | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) |
RU2018126105A (ru) | 2015-12-17 | 2020-01-17 | Астекс Терапьютикс Лимитед | Хинолин-3-карбоксамиды в качестве ингибиторов h-pgds |
US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
CA3009324A1 (fr) | 2015-12-23 | 2017-06-29 | President And Fellows Of Harvard College | Analogues de la cortistatine et leurs utilisations |
SG10201913587WA (en) | 2016-02-05 | 2020-02-27 | Denali Therapeutics Inc | Inhibitors of receptor-interacting protein kinase 1 |
JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ. ホフマン-ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
WO2019204537A1 (fr) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | Dérivés de n-[4-oxo-2,3-dihydro-1,5-benzoxazépin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide et composés apparentés en tant qu'inhibiteurs de la kinase rip1 pour le traitement, par exemple, du syndrome du côlon irritable (ibs) |
EP4025568A1 (fr) * | 2019-09-06 | 2022-07-13 | Rigel Pharmaceuticals, Inc. | Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation |
AR121717A1 (es) * | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
-
2016
- 2016-07-01 AU AU2016287581A patent/AU2016287581B2/en active Active
- 2016-07-01 MA MA042302A patent/MA42302A/fr unknown
- 2016-07-01 PE PE2022000233A patent/PE20221048A1/es unknown
- 2016-07-01 MA MA053835A patent/MA53835A/fr unknown
- 2016-07-01 CA CA2988601A patent/CA2988601C/fr active Active
- 2016-07-01 CN CN202010119812.3A patent/CN111269221B/zh active Active
- 2016-07-01 TW TW110115743A patent/TWI788830B/zh active
- 2016-07-01 CN CN202110232427.4A patent/CN112979660A/zh active Pending
- 2016-07-01 EP EP16738985.7A patent/EP3317269B1/fr active Active
- 2016-07-01 MX MX2017016482A patent/MX2017016482A/es unknown
- 2016-07-01 KR KR1020197037917A patent/KR102603915B1/ko active IP Right Grant
- 2016-07-01 EP EP20169511.1A patent/EP3760625B1/fr active Active
- 2016-07-01 MY MYPI2019006777A patent/MY192762A/en unknown
- 2016-07-01 PE PE2017002860A patent/PE20180501A1/es unknown
- 2016-07-01 ES ES16738985T patent/ES2930749T3/es active Active
- 2016-07-01 JP JP2017568057A patent/JP6785252B2/ja active Active
- 2016-07-01 US US15/200,058 patent/US10988459B2/en active Active
- 2016-07-01 CR CR20170573A patent/CR20170573A/es unknown
- 2016-07-01 WO PCT/US2016/040659 patent/WO2017004500A1/fr active Application Filing
- 2016-07-01 CN CN201680039261.1A patent/CN107849023B/zh active Active
- 2016-07-01 RU RU2018104092A patent/RU2716136C2/ru active
- 2016-07-01 SG SG10201913880XA patent/SG10201913880XA/en unknown
- 2016-07-01 KR KR1020187003088A patent/KR102104911B1/ko active IP Right Grant
- 2016-07-01 UA UAA201800850A patent/UA122150C2/uk unknown
- 2016-07-01 CA CA3094197A patent/CA3094197C/fr active Active
- 2016-07-01 PL PL16738985.7T patent/PL3317269T3/pl unknown
- 2016-07-01 TW TW105120997A patent/TWI763630B/zh active
-
2017
- 2017-11-17 ZA ZA2017/07812A patent/ZA201707812B/en unknown
- 2017-11-21 IL IL255830A patent/IL255830B/en active IP Right Grant
- 2017-12-15 MX MX2021002978A patent/MX2021002978A/es unknown
- 2017-12-28 CO CONC2017/0013709A patent/CO2017013709A2/es unknown
- 2017-12-29 CL CL2017003486A patent/CL2017003486A1/es unknown
-
2018
- 2018-01-03 PH PH12018500034A patent/PH12018500034A1/en unknown
- 2018-08-31 HK HK18111219.2A patent/HK1251899A1/zh unknown
-
2019
- 2019-05-16 AU AU2019203444A patent/AU2019203444B2/en active Active
-
2020
- 2020-05-03 IL IL274391A patent/IL274391B/en unknown
- 2020-10-26 JP JP2020179045A patent/JP7190471B2/ja active Active
- 2020-11-19 CL CL2020003007A patent/CL2020003007A1/es unknown
-
2021
- 2021-03-10 US US17/198,238 patent/US20220348559A1/en active Pending
- 2021-04-20 AU AU2021202398A patent/AU2021202398A1/en not_active Abandoned
-
2022
- 2022-11-29 AU AU2022279425A patent/AU2022279425A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53835A (fr) | Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoires | |
MA46228A (fr) | Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll | |
MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
WO2017011820A3 (fr) | Peptides inhibiteurs du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires | |
MA47013A (fr) | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase | |
DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
IL265902A (en) | Complex mixtures containing cannabinoids for the treatment of neurodegenerative diseases | |
MA56412A (fr) | Thérapie par l'arn messager pour le traitement des maladies articulaires | |
MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
HK1256795A1 (zh) | 可用於治療自身免疫疾病的二吡唑基衍生物 | |
MA47521A (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
MA47736A (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 | |
IL269853A (en) | Proteins for the treatment of epithelial barrier activity disorders | |
MA53568A (fr) | Médicaments pour le traitement de maladies ophtalmiques | |
MX2020011668A (es) | Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales. | |
ZA201902111B (en) | Substituted pyrido[3,4¿b]indoles for the treatment of cartilage disorders | |
MA43800A (fr) | Octréotide par voie orale pour le traitement de maladies | |
MA53614A (fr) | Protéine pour le traitement de maladies inflammatoires | |
IL266779A (en) | A method for early drug selection for protein misfolding diseases | |
DK3452465T3 (da) | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme | |
EA201791937A1 (ru) | Противовоспалительные полипептиды | |
IL252200B (en) | A process for the purification of receptor tyrosine kinase inhibitor axl "r 428" | |
IL263177A (en) | Fused bicyclic compounds for the treatment of disease | |
FR3048968B1 (fr) | Procede de preparation d'alkylamines | |
FR3049599B1 (fr) | Procede de preparation de l'hexafluorobutadiene. |